Literature DB >> 15218241

Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.

R L Stallings1, P Carty, L McArdle, M Mullarkey, M McDermott, A O'Meara, E Ryan, D Catchpoole, F Breatnach.   

Abstract

Neuroblastoma, one of the most common tumors of childhood, presents at diagnosis with a vast number of recurrent chromosomal imbalances that include hyperdiploidy for whole chromosomes, partial loss of 1p, 3p, 4p, 11q, 14q, partial gain of 1q, 7q, 17q and amplification of MYCN. These abnormalities are nonrandomly distributed in neuroblastoma as loss of 3p and 11q rarely occur in MYCN amplified neuroblastomas. Here, we report on a patient who had a non-MYCN amplified 3p-/11q- neuroblastoma at diagnosis who subsequently developed a high level of MYCN amplification in bone marrow metastases 41 months after induction of complete remission. The tumor at diagnosis had low level unbalanced gain of distal 2p. In order to assess the frequency of low level gain of distal 2p in neuroblastoma, we examined the comparative genomic hybridization results from 60 neuroblastomas. Among non-MYCN amplified neuroblastomas, 8/45 (18%) had low level gain of distal 2p. Low level gain for a segment of 2p (i.e. a region larger than the 2p23-->p24 undergoing amplification) was also detected in five of the 15 tumors that had high level MYCN amplification. The possibility that low level gain of distal 2p is a risk factor for high level MYCN amplification is discussed. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15218241     DOI: 10.1159/000078560

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  5 in total

1.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.

Authors:  Andrey V Reshetnyak; Phillip B Murray; Xiarong Shi; Elizabeth S Mo; Jyotidarsini Mohanty; Francisco Tome; Hanwen Bai; Murat Gunel; Irit Lax; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 3.  Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade.

Authors:  Li Zhou; Daniel Catchpoole
Journal:  Transl Pediatr       Date:  2015-04

4.  Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain.

Authors:  Katarzyna Szewczyk; Aleksandra Wieczorek; Wojciech Młynarski; Szymon Janczar; Mariola Woszczyk; Zuzanna Gamrot; Radosław Chaber; Mariusz Wysocki; Monika Pogorzała; Mirosław Bik-Multanowski; Walentyna Balwierz
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

5.  Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

Authors:  G Schleiermacher; J Michon; I Huon; C Dubois d'Enghien; J Klijanienko; H Brisse; A Ribeiro; V Mosseri; H Rubie; C Munzer; C Thomas; D Valteau-Couanet; A Auvrignon; D Plantaz; O Delattre; J Couturier
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.